Intratumoral hu14.18–IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention

hu14.18–IL-2 (IC) is an immunocytokine consisting of human IL-2 linked to hu14.18 mAb, which recognizes the GD2 disialoganglioside. Phase 2 clinical trials of i.v. hu14.18–IL-2 (i.v.-IC) in neuroblastoma and melanoma are underway and have already demonstrated activity in neuroblastoma. We showed pre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Yang, Richard K., Kalogriopoulos, Nicholas A., Rakhmilevich, Alexander L., Ranheim, Erik A., Seo, Songwon, Kim, KyungMann, Alderson, Kory L., Gan, Jacek, Reisfeld, Ralph A., Gillies, Stephen D., Hank, Jacquelyn A., Sondel, Paul M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: AAI 2012
Schlagworte:
Clinical Immunology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3424361/
https://ncbi.nlm.nih.gov/pubmed/22844125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1200934
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge